G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate
Valentina Sica,Valentina Sica,José Manuel Bravo-San Pedro,José Manuel Bravo-San Pedro,V. Izzo,V. Izzo,Jonathan Pol,Jonathan Pol,Sandra Pierredon,David Enot,David Enot,Sylvère Durand,Sylvère Durand,Noélie Bossut,Noélie Bossut,Alexis Chery,Alexis Chery,Sylvie Souquere,Gérard Pierron,Evangelia Vartholomaiou,Naoufal Zamzami,Naoufal Zamzami,Thierry Soussi,Thierry Soussi,Thierry Soussi,Allan Sauvat,Allan Sauvat,Laura Mondragón,Laura Mondragón,Oliver Kepp,Oliver Kepp,Lorenzo Galluzzi,Jean-Claude Martinou,Holger Hess-Stumpp,Karl Ziegelbauer,Guido Kroemer,Maria Chiara Maiuri,Maria Chiara Maiuri +37 more
TL;DR: DMKG, a cell-permeable precursor of α-ketoglutarate that lacks toxicity on its own, kills cancer cells when combined with B87 or other inhibitors of OXPHOS, unveiling a metabolic liability of human cancer cells that may be harnessed for the development of therapeutic regimens.
Journal ArticleDOI
Trans-Fats Inhibit Autophagy Induced by Saturated Fatty Acids.
Allan Sauvat,Guo Chen,Kevin Müller,Mingming Tong,Fanny Aprahamian,Sylvère Durand,Giulia Cerrato,Lucillia Bezu,Marion Leduc,Joakim Franz,Patrick Rockenfeller,Junichi Sadoshima,Frank Madeo,Oliver Kepp,Guido Kroemer +14 more
TL;DR: It is concluded that the well-established, though mechanistically enigmatic toxicity of trans-unsaturated fatty acids may reside in their capacity to abolish cytoprotective stress responses induced by saturated fatty acids.
Journal ArticleDOI
Novel immune checkpoint blocker approved for the treatment of advanced melanoma
TL;DR: Pembrolizumab, which has been developed by Merck & Co.
Journal ArticleDOI
When less is more: hormesis against stress and disease
TL;DR: A short overview of current evidence in favor of the cytoprotective impact of hormesis is provided, as well as of its underlying molecular mechanisms, to help clarify the conceptual and potentially therapeutic importance of this phenomenon.
Journal ArticleDOI
Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate in vivo.
David Enot,Mireia Niso-Santano,Sylvère Durand,Alexis Chery,Federico Pietrocola,Erika Vacchelli,Frank Madeo,Lorenzo Galluzzi,Guido Kroemer +8 more
TL;DR: Mass spectrometry coupled to principal component analysis revealed that PA and OL induce well distinguishable changes in circulating metabolites as well as in the metabolic profile of the liver, heart, and skeletal muscle.